First Copycat Biotech Drug Spurs $250B Obamacare Savings
The first U.S. approval of the “generic” biologic prescription version of the widely prescribed anti-infective cancer medicine Neupogen officially opens the door to a new era in cheaper drugs that could save the U.S. health care system tens of billions of dollars a year.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Bruce Japsen Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Filgrastim | Health | Health Management | Neupogen | Pharmaceuticals